Grownup Stem Cell Analysis Bill Passes Out of Congressional Committee
A critical public health reauthorization bill authored by Rep. Chris Smith (R-NJ)—HR 5160, the Stem Cell Therapeutic and Research Reauthorization Act of 2025, today passed out of the House Committee on Energy and Commerce’s Subcommittee on Health, where they now head to the full committee markup slated for next week.
“I am grateful to the Subcommittee on Health, especially Chairman Morgan Griffith (R-VA), for advancing these critical, life-enhancing bills to assist the millions of Americans suffering from chronic health conditions,” said Smith.
Click Like if you are pro-life to like the LifeNews Facebook page!
“HR 5160 will authorize more than $280 million over five years for the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory, ensuring that two collaborative programs can continue providing treatments and therapies derived from ethically-sourced stem cell lines,” stated Smith, the author of the original law (the Stem Cell Therapeutic and Research Act of 2005 – PL 109-129) that created those programs and connected patients with genetically-matched, ethically-gleaned stem cells.
“Uninterrupted funding and support for these programs will save more lives, as stem cell treatments have been used to treat, and even cure, more than 75 diseases, including leukemia, lymphoma and sickle cell anemia,” Smith continued. “I urge the Committee and House Leadership to quickly advance this much-needed reauthorization, and I look forward to seeing it be signed into law.”
